Sweden must apply for Bangladesh’s approval for human trial against nasal Covid jab
FE REPORT |
Published:
24 January 2022 09:08:23
| Updated:
24 January 2022 17:30:22
The Swedish Karolinska Institute will apply for ethical approval from the Bangladesh Medical Research Council (BMRC) to start a human trial of its developed nasal Covid-19 vaccine here.
ISR has already designated Bangladesh Clinical Trials Ltd as its contract research organization.
The two organizations also signed a Memorandum of Understanding (MoU) earlier on this.
Dr. Ahmedul Kabir, Rector of Mugda Medical College, and Dr. ABM Abdullah, former Dean of the Faculty of Medicine at Bangabandhu Sheikh Mujib Medical University, will serve as principal investigators if the trial is approved.
They work with the protocol for the clinical trial.
“We are in the final stages. We will soon submit their protocol to seek ethical approval from the BMRC,” said medical expert Dr ABM Abdullah.
After receiving the approval, he said, they would start testing the nasal vaccine here.
“We want to start the first phase of the clinical trial first. If it is successful, we will start phase-2 and phase-3 tracks together,” he said.
He also announced that they would administer two doses of the vaccine during a four-week break.
Dr. Ahmedul Kabir said that a nasal spray device is used to dry up the whole proteins.
“The good part of the system is that you do not have to store it in the refrigerator. Even people can administer the antidote on their own. They do not have to come to the vaccination site,” he said.
A total of 90 volunteers will take part in the test run of the first phase of the nasal vaccine.
Covid-19 vaccines, which are used worldwide, are currently being injected into the recipients’ muscles, but concerns have increased about their effectiveness in preventing infection with new variants in the absence of doses, while vaccines targeting the mucous membranes are not new.
There are many oral vaccines that are approved to fight infections such as polio and cholera.
In an article on July 21, Karolinska Institutet’s immunologist and T-cell researcher Marcus Buggert said that when infections occur in the mucous membrane of the nasal cavity and the T-cells, the immune system is primate.
[email protected]